BIRMINGHAM, Ala.--(BUSINESS WIRE)--BioDtech, Inc. (BDTI) an emerging life science company, today announced the release of EndoPrep™, the first product designed for the safety of genetically engineered and protein drugs. EndoPrep™ allows for the more accurate detection of a toxin associated with the production of antibodies, recombinant proteins and synthetic peptides which are the basis for new cancer, cardiovascular, neurological, infectious and metabolic diseases. The toxin is masked by these drugs in the current FDA approved methods for detection. EndoPrep™ removes the drug allowing the toxin to be exposed and detected by standard assays.
